Literature DB >> 16967374

Inhibition of carotis venous bypass graft disease by intraoperative nucleic acid-based therapy in rabbits.

B Kusch1, S Waldhans, A Sattler, A Wagner, M Hecker, R Moosdorf, S Vogt.   

Abstract

BACKGROUND: Bypass graft stenosis after venous revascularisation procedures is characterised by massive neointimal and vascular smooth muscle cell proliferation triggered via endothelin-1 synthesis in the vessel wall. Decoy oligodesoxynucleotides (ODN) against the transcription factor activator protein-1 (AP-1) inhibits pre-pro-endothelin-1 expression.
METHODS: In 20 rabbits, an end-to-side jugular vein bypass to the carotid artery was performed: (group A) 8 grafts were treated with consensus AP-1 decoy ODN, (group B) 8 with mutated control ODN and (group C) 4 received no treatment. Explantation, histomorphometric and immunohistochemical evaluation was performed after 28 days.
RESULTS: Median intimal thickness of groups: (A) 28.3 microm, (B) 48.4 microm, (C) 71.1 microm. The decoy ODN-treated group showed a significant reduction of neointima formation ( P = 0.029) and a downregulation of the endothelin receptor.
CONCLUSIONS: In this model, neointima formation was reduced by local transfection with consensus decoy ODN against AP-1. Endothelin A and B receptor expression is downregulated. Molecular target nucleic acid-based therapies seem to be a future means of overcoming neointima proliferation in pressure-induced venous graft failure. Intraoperative local application makes it easy to use in routine revascularisation procedures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16967374     DOI: 10.1055/s-2006-924410

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  1 in total

Review 1.  Mechanisms of vein graft adaptation to the arterial circulation: insights into the neointimal algorithm and management strategies.

Authors:  Akihito Muto; Lynn Model; Kenneth Ziegler; Sammy D D Eghbalieh; Alan Dardik
Journal:  Circ J       Date:  2010-07-01       Impact factor: 2.993

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.